Bajpai Jyoti, Kant Surya, Verma Ajay, Patwa Ajay K, Atam Virendra, Chaudhary Shyam C, Pandey Anuj
Pulmonology, King George's Medical University, Lucknow, IND.
Gastroenterology, King George's Medical University, Lucknow, IND.
Cureus. 2022 May 26;14(5):e25378. doi: 10.7759/cureus.25378. eCollection 2022 May.
Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by SARS CoV-2 that emerged in Wuhan, China, and has rapidly spread worldwide. The mortality rate of critically ill COVID-19 patients is high.
To assess the severity, different clinical symptoms, and comorbidities of COVID-19 pneumonia in vaccinated vs. non-vaccinated patients.
In this single-center, cross-sectional study, 142 patients with COVID-19 were enrolled. The clinical characteristics, comorbidities, severity, and outcomes were also assessed.
Of the 142 patients, 92 (64.8%) were males, with a mean age of (56.00±14.81) years. Among them, 62 (43.7%) were aged above 60 years. Of these, 92 (64.7%) had comorbidities. The patients were divided into two groups: unvaccinated and those who received at least one dose of the vaccine within six months. The demographic characteristics of the two groups were similar except for gender. In the vaccinated group, most of the patients were males. Most patients in the non-vaccinated group had a severe illness, whereas most patients in the vaccinated group had mild to moderate disease. Only 26% of the vaccinated group experienced severe illness compared to 71.5% in the unvaccinated group. In addition, the all-cause 30-day mortality in the non-vaccinated population was higher than that in the vaccinated population. However, this difference was not statistically significant (12.5% vs. 7.1%). On the contrary, there was no difference in the length of the intensive care unit or total hospital stay between the two groups.
Severe COVID-19 had the worst outcome in the unvaccinated patients. Most partially vaccinated patients got infected before developing immunity, and a small percentage of completely immunized patients who were infected were likely non-responders. Receiving at least one vaccination dose significantly reduced illness severity.
2019年冠状病毒病(COVID-19)是一种由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的新型传染病,在中国武汉出现,并迅速在全球传播。危重型COVID-19患者的死亡率很高。
评估接种疫苗与未接种疫苗的COVID-19肺炎患者的病情严重程度、不同临床症状及合并症情况。
在这项单中心横断面研究中,纳入了142例COVID-19患者。同时评估了患者的临床特征、合并症、病情严重程度及预后情况。
142例患者中,男性92例(64.8%),平均年龄为(56.00±14.81)岁。其中,62例(43.7%)年龄在60岁以上。这些患者中,92例(64.7%)有合并症。患者被分为两组:未接种疫苗组和在6个月内至少接种一剂疫苗的患者。除性别外,两组的人口统计学特征相似。在接种疫苗组中,大多数患者为男性。未接种疫苗组的大多数患者病情严重,而接种疫苗组的大多数患者病情为轻至中度。接种疫苗组仅有26%的患者病情严重,而未接种疫苗组为71.5%。此外,未接种疫苗人群的全因30天死亡率高于接种疫苗人群。然而,这种差异无统计学意义(12.5%对7.1%)。相反,两组在重症监护病房住院时间或总住院时间方面无差异。
未接种疫苗的患者中,重症COVID-19的预后最差。大多数部分接种疫苗的患者在产生免疫力之前就被感染,而一小部分感染的完全免疫患者可能是无反应者。接种至少一剂疫苗可显著降低疾病严重程度。